Evidence map›Paper›PMID 39356149›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Racial and Ethnic Disparities in Hepatitis C Care in Reproductive-Aged Women With Opioid Use Disorder.

Breanne E Biondi, Sarah Munroe, Claudine Lavarin, Megan R Curtis, Benjamin Buzzee, Sara Lodi, Rachel L Epstein

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Gaps in the Hepatitis C Prenatal and Postpartum Care Cascade: Rationale for Treatment in Pregnancy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Breanne E BiondiDepartment of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0002-5203-9455
Sarah MunroeSection of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA.ORCID 0009-0009-5591-1454
Claudine LavarinDepartment of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts, USA.
Megan R CurtisMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Benjamin BuzzeeSection of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA.
Sara LodiDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0002-9419-7830
Rachel L EpsteinSection of Infectious Diseases, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH, DEBBIE M. CHENG · 1998 to 2026
$51.7M
Utilization of health services after engagement with opioid use disorder (OUD) treatment provider by individuals with and without post-traumatic stress disorderP30DA040500 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Yuhua Bao · 2015 to 2026
$20.7M
PROGRAM FOR AIDS CLINICAL RESEARCH TRAINING (PACRT)T32AI007433 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MARK J SIEDNER · 1992 to 2026
$11.4M
BU Clinical HIV/AIDS Research Training Program (BU-CHART)T32AI052074 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Benjamin P. Linas · 2003 to 2026
$6.7M
Integrated Care for Addiction, HIV and HCV Research and Education (ICAHRE)T32DA041898 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Rachel Sayko Adams, Michael D Stein · 2017 to 2026
$3.8M
Perinatal care as a venue to reduce opioid overdoses and hepatitis C virus incidence (PreVenT OD HCV)K01DA052821 · NIDA · BOSTON MEDICAL CENTER · PI Rachel Lee Epstein · 2022 to 2026
$959k
Charles A. King TrustCharles A. King Trust Postdoctoral Research FellowshipNational Institute of Allergy and Infectious Disease T32AI052074National Institute of Drug Abuse T32DA041898NIAID NIH HHS P30 AI042853NIAID NIH HHS T32 AI007433NIAID NIH HHS T32 AI052074NIDA NIH HHS K01 DA052821NIDA NIH HHS P30 DA040500NIDA NIH HHS T32 DA041898Providence/Boston Center for AIDS Research
6 · The paper itself

Abstract

backgroundIn the United States, hepatitis C virus (HCV) diagnoses among reproductive-aged women are increasing amidst the ongoing opioid and drug overdose epidemic. While previous studies document racial and ethnic disparities in HCV testing and treatment in largely male populations, to our knowledge no national studies analyze these outcomes in reproductive-aged women with opioid use disorder (OUD).

methodsWe analyzed data from a cohort of reproductive-aged women (aged 15-44 years) with diagnosed OUD captured in the TriNetX Research Network, a network of electronic health records from across the United States. Using a log-binomial model, we assessed differences in achieving HCV cascade of care stages (HCV antibody testing, HCV infection [positive HCV RNA test result], linkage to care, and HCV treatment) by race and ethnicity.

resultsFrom 2014 to 2022, 44.6% of the cohort were tested for HCV antibody. Asian and black/African American individuals had a lower probability of having an HCV antibody test than white individuals (risk ratio, 0.77 [95% confidence interval, .62-.96] and 0.76 [.63-.92], respectively). Among those with HCV infection, only 9.1% were treated with direct-acting antivirals. Hispanic/Latinx individuals had a higher probability of treatment than non-Hispanic/Latinx individuals (risk ratio, 1.63 [95% confidence interval, 1.01-2.61]).

conclusionsFew reproductive-aged women with OUD are tested or treated for HCV. Disparities by race and ethnicity in HCV testing further exacerbate the risk of perinatal transmission and disease progression among minoritized communities. Interventions are needed to improve overall rates of and equity in HCV screening and treatment for reproductive-aged women.

Indexed as

EthnicityHealthcare DisparitiesHepatitis COpioid-Related DisordersAdolescentAdultCohort StudiesFemaleHepacivirusHepatitis C AntibodiesHispanic or LatinoHumansRacial GroupsUnited StatesWhiteYoung AdultHepatitis C Antibodiesdisparitieshepatitis C virusopioid use disorderreproductive-aged females

Identifiers

PMID39356149
PMCPMC11650893

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.